Identification of a coagulation-feature-associated lncRNA prognostic signature in prostate cancer

The tumor microenvironment is significantly influenced by activation of the coagulation cascade, which contributes to cancer advancement and metastatic dissemination. Nevertheless, the prognostic value and functional mechanisms of long non-coding RNAs (lncRNAs) related to coagulation processes in prostate cancer (PCa) have not been fully elucidated. The present study was designed to discover and verify differentially expressed lncRNAs linked to coagulation pathways, develop a risk prediction model for PCa patients, and investigate their associations with immune microenvironment dynamics and relevant biological functions. In this study obtained transcriptomic/clinical data for PCa patients from TCGA. To identify coagulation-feature-related lncRNAs, we first screened via spearman correlation, then filtered for differential expression (|log₂FC|>1, P < 0.05) between PCa and paracancerous tissues. Cohorts were split 2:1 into training/validation sets. In training, univariate Cox plus LASSO-Cox selected prognosis-related lncRNAs to build a risk model. Model performance was validated in the validation cohort. Patients were stratified into high/low-risk groups by median risk score. A integrative nomogram was developed incorporating the risk score and clinical indexs to estimate probabilities of 1-, 3-, and 5-year biochemical recurrence-free survival (BRFS). This combined model was compared against conventional clinical indexs to evaluate its discriminative capacity. Furthermore, pathway enrichment analysis was carried out to uncover signaling mechanisms predominantly active in high-risk group, and immune cell infiltration patterns were analyzed to delineate features of the tumor immune microenvironment. Finally, functional experiments using PCa cell lines were performed to assess the oncogenic role of a selected lncRNA representative of the coagulation-associated signature. A prognostic prediction model based on lncRNAs related to coagulation was developed. And pathway enrichment analysis revealed significant activation of immune-related pathways among high-risk patients. Further immune infiltration profiling indicated distinct patterns of immune-cell composition and differential expression of immune-related factors between the high- and low-risk groups. Functional validation through in vitro experiments confirmed that silencing SLC9A3-AS1 significantly suppressed the proliferative, migratory, and invasive capacities of PCa cell lines, underscoring its promotive role in PCa oncogenesis. Through developing and validating a coagulation-feature-associated lncRNA prognostic model, we linked these molecules to PCa biology and its tumor immune microenvironment. This signature may serve as prognostic biomarkers and therapeutic targets for PCa precision management.